SPECT/CT and ex vivo biodistribution analysis revealed similar pharmacokinetics of [111In]In-CD3xTRP1 (figure 3B,D), but B16F10 tumor uptake was lower than KPC3-TRP1 tumor uptake, although not statistically significant (25.1%ID/g±15.1%ID/g vs 33.5%ID/g±15.4%ID/g, p=ns) (online supplemental table S1). Here, TYRP1 is linked to neoplasm.